Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?

Benzer Materyaller

• Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
  Yazar:: Gallyamov, Marat, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
  Yazar:: Niaz, Muhammad O, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
  Yazar:: Gadot, Moran, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• A Retrospective Analysis of the Safety and Activity of Lutetium‐177‐Prostate‐Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration‐Resistant Prostate Cancer
  Yazar:: Leibowitz, Raya, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years
  Yazar:: Majid Assadi, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-01-01)